<DOC>
	<DOCNO>NCT00984828</DOCNO>
	<brief_summary>The randomize control study newly-diagnosed myeloma patient 18-65 year old . All patient receive 4 cycle velcade Dexamethasone front-line therapy . Then patient randomized standard group receive single autologous hematopoietic stem cell transplantation standard conditioning melphalan 200mg/m2 study group receive single autologous hematopoietic stem cell transplantation condition melphalan 200mg/m2 + velcade follow 3 cycle velcade alone consolidation .</brief_summary>
	<brief_title>Randomized Study Velcade-based Regimen With Autologous Stem Cell Transplantation Newly-diagnosed Myeloma Patients</brief_title>
	<detailed_description>The randomize control study newly-diagnosed myeloma patient 18-65 year old . Newly-diagnosed myeloma patient enrol receive 4 cycle velcade Dexamethasone front-line induction therapy . All patient finish induction therapy randomize standard group study group . All patient mobilize cyclophosphamide G-CSF collect target 2x106 CD34+/kg undergo autologous stem cell transplantation . For standard group , patient receive single auto-SCT standard conditioning melphalan 200mg/m2 . The patient study group receive single auto-SCT conditioning melphalan 200mg/m2 add 4 dose velcade 1.0mg/m2 transplantation procedure follow 3 cycle velcade alone consolidation .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Man woman age 1865 newly diagnose Multiple Myeloma stem cell transplantation consider appropriate Measurable serum and/or urinary paraprotein European Cooperative Oncology Group performance status 03 Serum bilirubin &lt; 1.5x upper limit normal ( ULN ) Serum alanine transaminase ( ALT ) /aspartate transaminase value &lt; 2.5 x ULN Subjects ( legally acceptable representative ) must sign informed consent document indicate understand purpose procedure require study willing participate study Woman child bear potential Nonsecretory MM Serum creatinine &gt; 400 Micromol/l initial resuscitation patient previous Grade 24 peripheral neuropathy Uncontrolled diabetes ( receive antidiabetic agent , subject must stable dose least 3 month first dose study drug ) Uncontrolled severe cardiovascular disease include myocardial infarction within 6 month enrollment , uncontrolled angina , clinically significant pericardial disease , IIIIV heart failure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>multiple myeloma</keyword>
	<keyword>autologous stem cell transplantation</keyword>
	<keyword>velcade</keyword>
</DOC>